ACLX Quote, Financials, Valuation and Earnings

Agios Pharmaceuticals has a net margin of -99.37% compared to Arcellx's net margin of -1115.71%. Arcellx's return on equity of -9.11% beat Agios Pharmaceuticals's return on equity of 71.3%.

Arcellx has a consensus price target of $116.38, signalling upside risk potential of 47.16%. On the other hand Agios Pharmaceuticals has an analysts' consensus of $57.29 which suggests that it could grow by 71.51%. Given that Agios Pharmaceuticals has higher upside potential than Arcellx, analysts believe Agios Pharmaceuticals is more attractive than Arcellx.

Arcellx has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Agios Pharmaceuticals has a beta of 0.798, suggesting its less volatile than the S&P 500 by 20.182%.

Arcellx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agios Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcellx pays -- of its earnings as a dividend. Agios Pharmaceuticals pays out -- of its earnings as a dividend.

Arcellx quarterly revenues are $26M, which are larger than Agios Pharmaceuticals quarterly revenues of $9M. Arcellx's net income of -$25.9M is lower than Agios Pharmaceuticals's net income of $947.9M. Notably, Arcellx's price-to-earnings ratio is -- while Agios Pharmaceuticals's PE ratio is 2.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcellx is 26.52x versus 57.80x for Agios Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Catalyst Pharmaceuticals has a net margin of -99.37% compared to Arcellx's net margin of 34.1%. Arcellx's return on equity of -9.11% beat Catalyst Pharmaceuticals's return on equity of 27.81%.

Arcellx has a consensus price target of $116.38, signalling upside risk potential of 47.16%. On the other hand Catalyst Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 47.19%. Given that Catalyst Pharmaceuticals has higher upside potential than Arcellx, analysts believe Catalyst Pharmaceuticals is more attractive than Arcellx.

Arcellx has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Catalyst Pharmaceuticals has a beta of 0.748, suggesting its less volatile than the S&P 500 by 25.213%.

Arcellx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catalyst Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcellx pays -- of its earnings as a dividend. Catalyst Pharmaceuticals pays out -- of its earnings as a dividend.

Arcellx quarterly revenues are $26M, which are smaller than Catalyst Pharmaceuticals quarterly revenues of $128.7M. Arcellx's net income of -$25.9M is lower than Catalyst Pharmaceuticals's net income of $43.9M. Notably, Arcellx's price-to-earnings ratio is -- while Catalyst Pharmaceuticals's PE ratio is 18.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcellx is 26.52x versus 5.80x for Catalyst Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Gilead Sciences has a net margin of -99.37% compared to Arcellx's net margin of 16.61%. Arcellx's return on equity of -9.11% beat Gilead Sciences's return on equity of 0.64%.

Arcellx has a consensus price target of $116.38, signalling upside risk potential of 47.16%. On the other hand Gilead Sciences has an analysts' consensus of $98.92 which suggests that it could grow by 4.78%. Given that Arcellx has higher upside potential than Gilead Sciences, analysts believe Arcellx is more attractive than Gilead Sciences.

Arcellx has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.175, suggesting its less volatile than the S&P 500 by 82.499%.

Arcellx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences offers a yield of 3.26% to investors and pays a quarterly dividend of $0.77 per share. Arcellx pays -- of its earnings as a dividend. Gilead Sciences pays out 67.24% of its earnings as a dividend. Gilead Sciences's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Arcellx quarterly revenues are $26M, which are smaller than Gilead Sciences quarterly revenues of $7.5B. Arcellx's net income of -$25.9M is lower than Gilead Sciences's net income of $1.3B. Notably, Arcellx's price-to-earnings ratio is -- while Gilead Sciences's PE ratio is 1,049.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcellx is 26.52x versus 4.18x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of -99.37% compared to Arcellx's net margin of 11.99%. Arcellx's return on equity of -9.11% beat Johnson & Johnson's return on equity of 20.88%.

Arcellx has a consensus price target of $116.38, signalling upside risk potential of 47.16%. On the other hand Johnson & Johnson has an analysts' consensus of $172.53 which suggests that it could grow by 19.71%. Given that Arcellx has higher upside potential than Johnson & Johnson, analysts believe Arcellx is more attractive than Johnson & Johnson.

Arcellx has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.505, suggesting its less volatile than the S&P 500 by 49.522%.

Arcellx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 3.34% to investors and pays a quarterly dividend of $1.24 per share. Arcellx pays -- of its earnings as a dividend. Johnson & Johnson pays out 33.48% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Arcellx quarterly revenues are $26M, which are smaller than Johnson & Johnson quarterly revenues of $22.5B. Arcellx's net income of -$25.9M is lower than Johnson & Johnson's net income of $2.7B. Notably, Arcellx's price-to-earnings ratio is -- while Johnson & Johnson's PE ratio is 24.06x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcellx is 26.52x versus 4.03x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.